Morris Kandinov LLP has filed an action alleging that investors in Decarbonization Plus Acquisition Corporation were misled by its board of directors prior to the acquisition of Hyzon Motors Inc. (HYZN) in July 2021.

Vice Chancellor Zurn denies defendants’ motion to dismiss in case arising from the collapse of the Infinity Q Diversified Alpha Fund.

Morris Kandinov LLP is representing an investor in the Infinity Q Diversified Alpha Fund in connection with a motion to stop a proposed settlement on unfair terms.

Morris Kandinov LLP has filed a complaint on behalf of investors in the Tortoise Energy Infrastructure Corp. and the Tortoise Midstream Energy Fund, Inc., which incurred over $1 billion in losses during their liquidity crisis and collapse in early 2020.

Morris Kandinov LLP has filed a class action complaint on behalf of investors in FAST Acquisitions Corp. to prevent the sponsor from dissolving the SPAC without first distributing the SPAC’s $23.7 million in net assets to investors.

Morris Kandinov has filed an action on behalf of the High Income Securities Fund in connection with its purchase of preferred stock issued by Cedar Realty Trust, Inc.

Morris Kandinov LLP has filed an action seeking books and records in connection with its client’s investigation of misconduct at Lordstown Motors (RIDE).

Morris Kandinov LLP has filed two cases seeking to recover losses incurred by investors in the Infinity Q Diversified Alpha Fund (the “Fund”), a mutual fund that announced in early 2021 that it was liquidating because of extensive securities pricing errors that rendered its last reported net asset value (“NAV”) inaccurate.

Morris Kandinov LLP has filed a derivative suit on behalf of shareholders of the Fiduciary/Claymore Energy Infrastructure Fund (FMO) against the fund’s board of trustees and investment advisers. The case arises from the fund’s collapse after a liquidity crisis in early 2020 and the fund’s unexpected tax expenses disclosed thereafter.

Morris Kandinov LLP has filed a derivative complaint on behalf of a shareholder of Clover Health Investments, Corp. (CLOV) alleging, among other things, that the company concealed from investors, before going public through a SPAC, that the U.S. Department of Justice was actively investigating at least a dozen different matters relating to its business, which jeopardized the company’s ability to earn revenue through participation in the Medicare Advantage program.